Beijing Changxin Construction Investment

Beijing Changxin is a fully state-owned entity under the jurisdiction of the Beijing Changping District State-owned Assets Supervision and Administration Commission (SASAC). It operates as the direct investment and development platform for the district, executing infrastructure projects and strategic financing that align with municipal economic planning. There is no private or family ownership structure.

The firm's activities center on real estate development and long-term strategic financing within the Changping District. Its known balance sheet includes Grade A commercial office space in Future Science City and a portfolio of affordable residential projects. Beyond real assets, the firm provides long-term credit to key corporate entities, functioning as both developer and direct lender.

No. The entity is a government asset owner and municipal construction platform. Its form of corporate investment involves long-term credit arrangements, not minority equity stakes or venture capital-style rounds. It provides debt financing to strategic enterprises, such as biotech companies, to build local facilities, anchoring them within the district's industrial cluster.

Beijing Changxin is a major creditor and strategic partner to InnoCare Pharma Limited, a publicly listed biopharmaceutical company. The firm provided long-term financing to support InnoCare's facilities in Beijing, solidifying the company's presence in Changping. This relationship exemplifies the firm's mandate to use its balance sheet to anchor industrial development in Future Science City.

No. As a fully state-owned entity backed by the Changping SASAC, the firm does not raise funds from external limited partners or private investors. It operates as a captive asset owner using public capital to achieve economic development outcomes, not as a for-profit fund manager.